Decibel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Update

Pliant Therapeutics Announces Positive DSMB Safety Review and Initiation of Enrollment of Phase 2a Trial of Bexotegrast (PLN-74809) at 320 mg Dose in Primary Sclerosing Cholangitis

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022

Abata Therapeutics Appoints David Kaufman, M.D., Ph.D., to its Board of Directors

Pliant Therapeutics Announces Appointments of Darren Cline and Thomas McCourt to Board of Directors